Achievable predictive biomarkers for tumor response to mTOR inhibitors, as are explained in glioblastoma, breast and prostate cancer cells, could be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] As a result, this facts relies on preclinical assays, based upon in vitro cultured tumor mobile lines, which https://donaldn665ewn5.sasugawiki.com/user